wegovy glp-1 GLP-1s work but when they're stopped, the effects stop too: Expert Wegovy (Semaglutide) GLP-1 injection -

Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)

It is also one number, from one indication, from one trial

GLP-1 receptor agonists are frequently utilized in experimental settings to evaluate pharmacokinetics, receptor binding affinity, and molecular interactions involved in endocrine and metabolic research

However, an important shift is occurring Read More Oral GLP1 Therapy for Type 2 Diabetes: Why Pills Could Change the Playbook Jan 16, 2026 Articles, Blood Glucose Control, Diabetes, Obesity, Therapies, Top Articles, Type 2 Diabetes, Type 2 Diabetes 1,351 views The arrival of oral GLP1 therapy for type 2 diabetes marks a pivotal shift in diabetes care

GLP-1 based therapies: clinical implications for gastroenterologists

Arif Hafsa, Roughly 1M Canadians use Ozempic, similar drugs for weight loss, diabetes: study, CTVNews